Ionamin (Phentermine Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 4, 2017 Category: Drugs & Pharmacology Source Type: news

Suprenza (phentermine hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 3, 2017 Category: Drugs & Pharmacology Source Type: news

Qsymia (Phentermine and Topiramate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 6, 2017 Category: Drugs & Pharmacology Source Type: news

Fastin (Phentermine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 26, 2017 Category: Drugs & Pharmacology Source Type: news

Bucks company's weight-reduction pill gets FDA approval
The Food and Drug Administration has approved a Bucks County company ’s prescription weight reduction medicine, a low-dose and low-cost formulation of phentermine hydrochloride. Here are the details: Company: KVK Tech, a Newtown-based manufacturer of prescription and over-the-counter medicines. Product: Lomaira Approved as: An adjunct therapy for use over a shor t period of time for weight reduction in adults with an initial body mass index of 30 or more, or a body mass index of 27 or more with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 27, 2016 Category: Biotechnology Authors: John George Source Type: news

Bucks company's weight-reduction pill gets FDA approval
The Food and Drug Administration has approved a Bucks County company ’s prescription weight reduction medicine, a low-dose and low-cost formulation of phentermine hydrochloride. Here are the details: Company: KVK Tech, a Newtown-based manufacturer of prescription and over-the-counter medicines. Product: Lomaira Approved as: An adjunct therapy for use over a shor t period of time for weight reduction in adults with an initial body mass index of 30 or more, or a body mass index of 27 or more with… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 27, 2016 Category: Pharmaceuticals Authors: John George Source Type: news

KVK Tech Announces FDA-Approval of Lomaira(TM) (phentermine hydrochloride USP) 8 mg tablets, CIV, A Low-Cost, Low-Dose Phentermine That Can Be Used Up To Three Times Daily for Weight Reduction
NEWTOWN, Pa., Sept. 20, 2016 -- (Healthcare Sales & Marketing Network) -- KVK Tech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Lomaira™ (phentermine hydrochloride USP) 8 mg tablets CIV, a low-cost, low-dose prescrip... Biopharmaceuticals, FDA KVK Tech, Lomaira, phentermine, anorectic, obesity (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 20, 2016 Category: Pharmaceuticals Source Type: news

KVK Tech Announces FDA-Approval of Lomaira (phentermine hydrochloride USP) for Weight Reduction
NEWTOWN, Pa., Sept. 20, 2016 /PRNewswire/ -- KVK Tech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Lomaira (phentermine hydrochloride USP) 8 mg tablets CIV, a low-cost, low-dose prescription medicine used for a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 20, 2016 Category: Drugs & Pharmacology Source Type: news

Weight Loss Pills And Products Don't Work And Aren't Safe
Our ancestors lived in a feast or famine world. When you don't know where your next meal is coming from, or when it will arrive, the smart play is to pig out every time food is available. Our genes are programmed to extract as much energy as possible from what we eat and to store any extra energy in fat reservoirs, available in reserve for future famines. These deeply ingrained genetic tendencies worked great in the austere world of our ancestors, but are a disaster in our current world of refrigerators, ubiquitous fast food joints and milk shakes. Only one third of Americans are now able to maintain a normal weight; one ...
Source: Science - The Huffington Post - September 5, 2016 Category: Science Source Type: news

VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
MOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network) - VIVUS, Inc. (VVUS) today announced that the United States District Court for the District of New Jersey has issued a claim construction (Markman) ruling governing patent litigation brought by VIVU... Biopharmaceuticals, Generics, LitigationVIVUS, Actavis Laboratories, Teva Pharmaceutical, Qsymia, phentermine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2016 Category: Pharmaceuticals Source Type: news

Phentermine-topiramate tops competition for long-term weight loss
SAN DIEGO – Phentermine-topiramate was the most effective long-term weight loss drug, based on findings from a network meta-analysis from the University of California, San Diego. The investigators... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 20, 2016 Category: Endocrinology Source Type: news

Phentermine-topiramate tops competition for long-term weight loss
SAN DIEGO – Phentermine-topiramate was the most effective long-term weight loss drug, based on findings from a network meta-analysis from the University of California, San Diego. The investigators... (Source: Family Practice News)
Source: Family Practice News - June 20, 2016 Category: Primary Care Source Type: news

SGLT2 Inhibitor Adds to Weight Loss With Phentermine (CME/CE)
(MedPage Today) -- Canagliflozin may have synergistic effect with standard obesity drug (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news

Two Weight-Loss Drugs Have Highest Odds for 5% ReductionTwo Weight-Loss Drugs Have Highest Odds for 5% Reduction
Phentermine-topiramate and liraglutide were most likely among five obesity drugs approved by the FDA for long-term use to help people achieve a 5% weight loss over a year, a meta-analysis shows. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 15, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

5 weight loss drugs that actually work in the US
Scientists at the University of California found of the drugs - orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide - the last two, marketed as Qsymia, Saxenda and Victoza were most effective. (Source: the Mail online | Health)
Source: the Mail online | Health - June 15, 2016 Category: Consumer Health News Source Type: news

Experts rated weight-loss drugs and Qsymia came out on top
In the diet-medication sweepstakes, we have a winner. While all five drugs approved by the Food & Drug Administration for weight loss best a placebo in helping patients lose weight, a drug known commercially as Qsymia — a combination of the drugs phentermine and topiramate — most consistently prompted... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - June 14, 2016 Category: Science Authors: Melissa Healy Source Type: news

Revealed... the 5 weight loss drugs that ACTUALLY work - helping obese people shed up to 20lbs in a year
Scientists at the University of California found of the drugs - orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide - the last two, marketed as Qsymia, Saxenda and Victoza were most effective. (Source: the Mail online | Health)
Source: the Mail online | Health - June 14, 2016 Category: Consumer Health News Source Type: news

Study compares effectiveness of weight-loss drugs
In an analysis that included nearly 30,000 overweight or obese adults, compared with placebo, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were each associated with achieving at least 5 percent weight loss at 52 weeks, and phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 14, 2016 Category: Science Source Type: news

Phentermine-topiramate shows best chance of weight loss at 1 year
The combination weight-loss drug phentermine plus topiramate is associated with the highest odds of individuals being able to lose 5% of their body weight within 1 year, according to a meta-analysis... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 14, 2016 Category: Endocrinology Source Type: news

Phentermine-topiramate shows best chance of weight loss at 1 year
The combination weight-loss drug phentermine plus topiramate is associated with the highest odds of individuals being able to lose 5% of their body weight within 1 year, according to a meta-analysis... (Source: Family Practice News)
Source: Family Practice News - June 14, 2016 Category: Primary Care Source Type: news

Adipex-P (Phentermine Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 16, 2016 Category: Drugs & Pharmacology Source Type: news

Top-Selling Diet Drug Phentermine Is Cheap and Easy to Get
Phentermine, once part of the fen-phen drug combination taken off the market in the 1990s, is the best-selling diet pill today, often sold by doctors. (Source: NYT Health)
Source: NYT Health - July 4, 2015 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Phentermine Food and Drug Administration Weight Diet and Nutrition Source Type: news

Phentermine for weight loss
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - February 25, 2015 Category: Consumer Health News Source Type: news

phentermine and topiramate extended-release (Qsymia)
Title: phentermine and topiramate extended-release (Qsymia)Category: MedicationsCreated: 2/23/2015 12:00:00 AMLast Editorial Review: 2/23/2015 12:00:00 AM (Source: MedicineNet Weight Management General)
Source: MedicineNet Weight Management General - February 23, 2015 Category: Eating Disorders and Weight Management Source Type: news

Lorcaserin and Phentermine Safe Combo in Weight-Loss TrialLorcaserin and Phentermine Safe Combo in Weight-Loss Trial
A new pilot study examines the effect of adding a new weight-loss drug, lorcaserin, to an old appetite suppressant, phentermine. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 11, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Obesity Drug Safety Debate Escalates in Medical Journal Obesity Drug Safety Debate Escalates in Medical Journal
Arguments and accusations fly as physicians and others debate the FDA's wisdom in approving lorcaserin and phentermine-topiramate. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 4, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

phentermine, Adipex-P, Fastin (Discontinued), Obenix, Oby-Trim (Discontinued), Suprenza
Title: phentermine, Adipex-P, Fastin (Discontinued), Obenix, Oby-Trim (Discontinued), SuprenzaCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/25/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 25, 2014 Category: Drugs & Pharmacology Source Type: news

phentermine, Adipex-P, Fastin (Discontinued), Obenix, Oby-Trim (Discontinued), Suprenza
Title: phentermine, Adipex-P, Fastin (Discontinued), Obenix, Oby-Trim (Discontinued), SuprenzaCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/25/2014 12:00:00 AM (Source: MedicineNet Weight Management General)
Source: MedicineNet Weight Management General - July 25, 2014 Category: Eating Disorders and Weight Management Source Type: news

Is Belphen the Next Blockbuster Diet Drug?
(MedPage Today) -- Even though there are scant data, obesity researchers and patients have already put a name to a potential new weight-loss craze: Belphen, a combination of lorcaserin (Belviq) and phentermine. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 18, 2014 Category: Cardiology Source Type: news

New Obesity Drugs Provide 'Slim Pickings,' Say 2 ExpertsNew Obesity Drugs Provide 'Slim Pickings,' Say 2 Experts
There are still safety concerns with the 2 newest agents for obesity in the United States, lorcaserin and phentermine-topiramate, say 2 Dartmouth doctors. Medscape Medical News (Source: theHeart.org)
Source: theHeart.org - February 19, 2014 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Slim pickings for two weight-loss drugs?
Many medications for weight loss have been proposed or are under development. The Federal Drug Administration has approved few drugs for long-term weight loss, and some are no longer marketed because of safety issues, researchers of a new study have reported. In 2012, though, the FDA approved two drugs for long-term weight loss, lorcaserin hydrochloride (Belviq; Eisai Inc) and phentermine/topiramate (Qsymia; Vivus Inc). But Dartmouth researchers question how safe these two drugs are based on the FDA approval after one-year trials? (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 11, 2014 Category: Science Source Type: news

A safe, effective diet pill - the elusive holy grail
Trade in illegal, ineffective drugs flourishes as pharmaceutical industry repeatedly fails to produce successful pillAttempts to invent a safe and effective diet pill have foundered time and again, allowing the internet trade in illegal and ineffective herbal supplements and dangerous drugs, such as DNP, to flourish.A successful diet pill could make billions for the pharmaceutical industry, but efforts to date have ended in disaster, with patients harmed, drugs banned and massive compensation paid out.Fen-phen, an appetite suppressant, was the most spectacular failure. It was withdrawn in the US in 1997 after causing wides...
Source: Guardian Unlimited Science - January 14, 2014 Category: Science Authors: Sarah Boseley Tags: The Guardian Diets and dieting Drugs trade Healthcare industry World news Pharmaceuticals industry & wellbeing Health policy Society Politics UK news Life and style Public services policy Business Science Source Type: news

Qsymia Trims Sleep Apnea as Well as Weight (CME/CE)
ATLANTA (MedPage Today) -- Obese patients treated with the weight-loss combination of phentermine plus topiramate (Qsymia ER) for 28 weeks lost significant amounts of weight and also saw relief from their obstructive sleep apnea, researchers found. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 15, 2013 Category: Endocrinology Source Type: news

Combo Drug Qsymia Tops for Weight Loss
(MedPage Today) -- Overweight people who took the phentermine/topiramate combination diet drug Qsymia lost more weight than people taking a placebo or either drug alone in an industry-funded study. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - October 29, 2013 Category: Pediatrics Source Type: news

Diet drug controversy as US approves meds rejected by Europe
The decision from the Food and Drug Administration (FDA) to allow two anti-obesity drugs to be marketed in the US has been called into question by a senior doctor publishing in the BMJ. Dr. Sidney Wolfe, founder of the health research group at Public Citizen, says that the fact these drugs have been banned by the European regulator "puts the FDA to shame." Belviq (lorcaserin) and Qsymia (phentermine plus topiramate) are available as anti-obesity drugs in the US... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 23, 2013 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

New Evidence: Obesity Drug Phentermine Is Not AddictiveNew Evidence: Obesity Drug Phentermine Is Not Addictive
A new study reveals no withdrawal effects in those stopping phentermine, but 1 observer says this is insufficient to assuage concerns about the drug, which include potential cardiac toxicity. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Diet Drug Trims Hypertension Too (CME/CE)
SAN FRANCISCO (MedPage Today) -- The weight loss achieved with extended-release phentermine/topiramate (Qsymia) comes with corresponding blood pressure reduction for hypertensive patients, a subanalysis showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 20, 2013 Category: Cardiology Source Type: news

Stopping Phentermine After Long-Term Treatment Does Not Result In Amphetamine-Like Withdrawal
New research published at the European Congress on Obesity (ECO) shows that abrupt cessation after long-term use of the anti-obesity drug phentermine does not induce amphetamine-like withdrawal symptoms. The research is by Dr Ed Hendricks, Center for Weight Management*, Sacramento & Roseville, California, USA, and was funded by the American Society of Bariatric Physicians (ASBP). Phentermine is a psychostimulant drug of the phenethylamine class, with pharmacology similar to amphetamine... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 17, 2013 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

Withdrawal Not a Problem with Phentermine (CME/CE)
(MedPage Today) -- Patients taking phentermine long-term to treat obesity don't have to worry about withdrawal when they come off it, researchers found. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 15, 2013 Category: Primary Care Source Type: news

Qsymia: Data Find No Long-Term Heart Risk (CME/CE)
PHOENIX (MedPage Today) -- The more weight patients lost after 2 years on the diet drug Qsymia (phentermine/topiramate), the greater their improvements in cardiovascular risk markers, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 3, 2013 Category: Cardiology Source Type: news

EU rejects obesity drug Qsiva for the second time
Despite an appeal by Vivus, the European Medicines Agency has rejected the obesity treatment phentermine/topiramate ER for the second time. Any benefit "does not outweigh the risks," says the EMA. (Source: theHeart.org)
Source: theHeart.org - February 26, 2013 Category: Cardiology Source Type: news

EU Rejects Obesity Drug Qsiva for the Second TimeEU Rejects Obesity Drug Qsiva for the Second Time
Despite an appeal by Vivus, the European Medicines Agency has rejected the obesity treatment phentermine/topiramate extended release for the second time. Any benefit "does not outweigh the risks," says the EMA. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

CHMP recommends refusal of Qsiva® (phentermine/ topiramate) marketing authorisation following re-examination
Source: European Medicines Agency Area: News Following a re-examination of a previous opinion, the Committee for Medicinal Products for Human Use (CHMP) has confirmed its recommendation to refuse the marketing authorisation for Qsiva® (phentermine and topiramate), intended for the treatment of obesity.   The CHMP noted concerns about the long-term cardiovascular effects of Qsiva® (particularly those of the phentermine component, which is known to increase heart rate). There were additionally concerns about the long-term psychiatric and cognitive effects related to the topiramate component. Topiramate is ...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news

Pharmacist advises BBC Radio Berkshire about dodgy diet pills
Carol Trower, Chief Executive of the Berkshire Local Pharmaceutical Committee, was interviewed on BBC Radio Berkshire this week.  A local doctor practising at a private slimming clinic had received a warning from CQC for the way he prescribed phentermine and diethylpropion. Carol talked with (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 10, 2012 Category: Drugs & Pharmacology Source Type: news